Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Peregrine Pharmaceuticals Shares Plummet

By Pharmaceutical Processing | June 28, 2013

Shares of Peregrine Pharmaceuticals Inc. sank Thursday after the drug developer said it will stop studying a treatment combination involving its potential lung cancer drug bavituximab.

THE SPARK: The Tustin, Calif., company said a combination of bavituximab, carboplatin and a chemotherapy drug labeled paclitaxel did not produce a meaningful enough difference in overall survival in patients compared with carboplatin and paclitaxel alone. The company had just completed an analysis of data from a mid-stage study of the drug.

Peregrine said the combination involving bavituximab did produce an average overall survival of 14 months.

THE BIG PICTURE: Peregrine still plans to start a late-stage study by the end of the year of bavituximab combined with another chemotherapy drug, docetaxel. That combination will be delivered to patients with a form of lung cancer who have already tried another treatment.

Peregrine does not have any approved products, and bavituximab is its most advanced experimental drug. The company had more than $42 million in cash as of June 24. It said it has enough cash resources to fund operations for at least the next 12 months.

SHARE ACTION: Down nearly 25 percent, or 38 cents, to $1.17 in heavy trading Thursday morning, while broader indexes climbed about 1 percent. The stock closed Wednesday up 18 percent since the start of the year.

 

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE